Antiproteasomal agents in rectal cancer

Anti-Cancer Drugs

Volumn 22, Issue 4, 2011, Pages 341-350

  Conrad, Claudius ^a   Podolsky, Michael J ^a   Cusack, James C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antiproteasomal agents; chemotherapy; colorectal cancer; radiosensitizing agent; ubiquitin proteasome system

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; CAMPTOTHECIN; CARFILZOMIB; CEP 1612; CEP 18770; CURCUMIN; DIHYDROEPONEMYCIN; DISULFIRAM; DNA TOPOISOMERASE INHIBITOR; GLIOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LACTACYSTIN; MLN 9708; OXALIPLATIN; PACLITAXEL; PR 047; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P53; RADIOSENSITIZING AGENT; ROMIDEPSIN; SALINOSPORAMIDE A; TEMOZOLAMIDE; UBIQUITIN; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADVANCED CANCER; APOPTOSIS; BRAIN CANCER; BREAST CANCER; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURGERY; CELL CYCLE ARREST; COLORECTAL CANCER; DIARRHEA; FATIGUE; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HODGKIN DISEASE; HUMAN; HYPONATREMIA; HYPOTENSION; INFECTION; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCREAS CANCER; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RECTUM CARCINOMA; REVIEW; SENSORY NEUROPATHY; STOMACH CARCINOMA; UTERINE CERVIX CANCER; VOMITING; WEAKNESS;

CLINICAL TRIALS AS TOPIC; HUMANS; NEOADJUVANT THERAPY; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; RADIATION-SENSITIZING AGENTS; RECTAL NEOPLASMS; UBIQUITIN;

EID: 79952987601     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328342fedb     Document Type: Review

References (129)

1. World Health Organization. The global burden of disease: 2004 update. Geneva: WHO Press; 2008.
2. Ries LA, Kosary CL, Hankey BF, Miller BA, Edwards BK. SEER cancer statistics review 1973-1995. Bethesda, MD: National Cancer Institute; 1998.
3. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-479. (Pubitemid 28411135)
4. Naujokat C, Hoffmann S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 2002;82:965-980.
5. Reed SI. The ubiquitin-proteasome pathway in cell cycle control. Results Probl Cell Differ 2006;42:147-181. (Pubitemid 44856951)
6. Strehl B, Seifert U, Kruger E, Heink S, Kuckelkorn U, Kloetzel PM. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 2005;207:19-30. (Pubitemid 41415005)
7. Daniel KG, Kuhn DJ, Kazi A, Dou QP. Anti-angiogenic and anti-tumor properties of proteasome inhibitors. Curr Cancer Drug Targets 2005;5:529-541. (Pubitemid 41502564)
8. Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, et al. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci 2010;86:199-206.
9. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin e by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996;10:1979-1990. (Pubitemid 26346107)
10. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997;11:957-972. (Pubitemid 27199876)
11. Sudakin V, Ganoth D, Dahan A, Heller H, Hershko J, Luca FC, et al. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 1995;6:185-197.
12. Cayrol C, Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 1998;17:2437-2444. (Pubitemid 28544713)
13. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685.
14. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53 (1). Cancer Res 1996;56:2649-2654. (Pubitemid 26170702)
15. Buschmann T, Fuchs SY, Lee CG, Pan ZQ, Ronai Z. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell 2000;101:753-762.
16. Coutts AS, La Thangue NB. The p53 response: emerging levels of cofactor complexity. Biochem Biophys Res Commun 2005;331:778-785. (Pubitemid 40615508)
17. Eilers M, Schirm S, Bishop JM. The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J 1991;10:133-141. (Pubitemid 21905275)
18. Marcu KB, Bossone SA, Patel AJ. MYC function and regulation. Annu Rev Biochem 1992;61:809-860.
19. Saint-Ruf C, Gerbault-Seureau M, Viegas-Pequignot E, Zafrani B, Cassingena R, Dutrillaux B. Proto-oncogene amplification and homogeneously staining regions in human breast carcinomas. Genes Chromosomes Cancer 1990;2:18-26. (Pubitemid 20300431)
20. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076. (Pubitemid 32691956)
21. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159:2212-2221. (Pubitemid 127681011)
22. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1995;92:10599-10603. (Pubitemid 3009135)
23. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x (L). Mol Cell Biol 2000;20:2687-2695. (Pubitemid 30183487)
24. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin as Jr. NFkappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-1683.
25. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005;7:758-765.
26. Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 2001;115:279-286. (Pubitemid 34203489)
27. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et al. Role of the proteasome and NF-kappaB in streptococcal cell wallinduced polyarthritis. Proc Natl Acad Sci U S A 1998;95:15671-15676. (Pubitemid 29018758)
28. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-127. (Pubitemid 29045184)
29. Spiegelman VS, Slaga TJ, Pagano M, Minamoto T, Ronai Z, Fuchs SY. Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol Cell 2000;5:877-882.
30. Cusack JC Jr, Liu R, Baldwin as Jr. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res 2000;60:2323-2330. (Pubitemid 30262414)
31. Cusack JC Jr, Liu R, Xia L, Chao TH, Pien C, Niu W, et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 2006;12:6758-6764. (Pubitemid 44876845)
32. Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 2001;130:363-369. (Pubitemid 32721692)
33. Yu HG, Yu LL, Yang Y, Luo HS, Yu JP, Meier JJ, et al. Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology 2003;65:37-45. (Pubitemid 36829089)
34. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61:3535-3540. (Pubitemid 32694955)
35. Russo SM, Tepper JE, Baldwin as Jr, Liu R, Adams J, Elliott P, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001;50:183-193.
36. He H, Qi XM, Grossmann J, Distelhorst CW. c-Fos degradation by the proteasome. An early, Bcl-2-regulated step in apoptosis. J Biol Chem 1998;273:25015-25019. (Pubitemid 28443257)
37. Chadebech P, Brichese L, Baldin V, Vidal S, Valette A. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage. Biochem Biophys Res Commun 1999;262:823-827. (Pubitemid 29443742)
38. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A 2000;97:3850-3855. (Pubitemid 30226050)
39. Adachi M, Katsumura KR, Fujii K, Kobayashi S, Aoki H, Matsuzaki M. Proteasome-dependent decrease in Akt by growth factors in vascular smooth muscle cells. FEBS Lett 2003;554:77-80. (Pubitemid 37324818)
40. Wu W, Wang X, Zhang W, Reed W, Samet JM, Whang YE, et al. Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells. J Biol Chem 2003;278:28258-28263. (Pubitemid 36900027)
41. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
42. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, et al. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to taxol-induced apoptosis. Oncogene 2002;21:6510-6519. (Pubitemid 35155455)
43. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 1999;6:279-285. (Pubitemid 29221014)
44. Clevers H. Wnt breakers in colon cancer. Cancer Cell 2004;5:5-6. (Pubitemid 38121590)
45. Ilyas M. Wnt signalling and the mechanistic basis of tumour development. J Pathol 2005;205:130-144. (Pubitemid 40227986)
46. Dihlmann S, Kloor M, Fallsehr C, von Knebel Doeberitz M. Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells. Carcinogenesis 2005;26:1503-1512. (Pubitemid 41236043)
47. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A 1999;96:1603-1608. (Pubitemid 29098498)
48. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999;96:5522-5527. (Pubitemid 29234650)
49. Wong NA, Pignatelli M. Beta-catenin - a linchpin in colorectal carcinogenesis? Am J Pathol 2002;160:389-401.
50. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001;1:55-67. (Pubitemid 33741881)
51. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005;6:322-327. (Pubitemid 40590269)
52. McLellan EA, Bird RP. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res 1988;48:6187-6192. (Pubitemid 18266821)
53. Pretlow TP, Pretlow TG. Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? Biochim Biophys Acta 2005;1756:83-96. (Pubitemid 41781960)
54. Leow CC, Romero MS, Ross S, Polakis P, Gao WQ. Hath1, downregulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells. Cancer Res 2004;64:6050-6057. (Pubitemid 39129403)
55. Park ET, Oh HK, Gum JR Jr, Crawley SC, Kakar S, Engel J, et al. HATH1 expression in mucinous cancers of the colorectum and related lesions. Clin Cancer Res 2006;12:5403-5410. (Pubitemid 44497254)
56. Tsuchiya K, Nakamura T, Okamoto R, Kanai T, Watanabe M. Reciprocal targeting of Hath1 and beta-catenin by Wnt glycogen synthase kinase 3 beta in human colon cancer. Gastroenterology 2007;132:208-220. (Pubitemid 46108744)
57. Aragaki M, Tsuchiya K, Okamoto R, Yoshioka S, Nakamura T, Sakamoto N, et al. Proteasomal degradation of Atoh1 by aberrant Wnt signaling maintains the undifferentiated state of colon cancer. Biochem Biophys Res Commun 2008;368:923-929.
58. Xu J, Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 2000;97:4820-4825. (Pubitemid 30238641)
59. Kuwai T, Kitadai Y, Tanaka S, Hiyama T, Tanimoto K, Chayama K. Mutation of the von Hippel-Lindau (VHL) gene in human colorectal carcinoma: association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)-1alpha. Cancer Sci 2004;95:149-153. (Pubitemid 38404316)
60. Hu XT, Chen W, Zhang FB, Shi QL, Hu JB, Geng SM, et al. Depletion of the proteasome subunit PSMA7 inhibits colorectal cancer cell tumorigenicity and migration. Oncol Rep 2009;22:1247-1252.
61. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22:304-311. (Pubitemid 38725184)
62. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-338. (Pubitemid 28072702)
63. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP et al. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 2008;68:7283-7292.
64. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995;268:726-731.
65. Tomoda H, Omura S. Lactacystin, a proteasome inhibitor: discovery and its application in cell biology. Yakugaku Zasshi 2000;120:935-949.
66. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009;52:3028-3038.
67. Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006;66:6379-6386.
68. Cvek B, Dvorak Z. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discov Today 2008;13:716-722.
69. Kim KB, Myung J, Sin N, Crews CM. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett 1999;9:3335-3340.
70. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 1997;94:855-860. (Pubitemid 27074411)
71. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622. (Pubitemid 29269108)
72. Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002;16:433-443. (Pubitemid 34449723)
73. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361-369. (Pubitemid 37296062)
74. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-1428. (Pubitemid 32708698)
75. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-2645. (Pubitemid 29437352)
76. Voutsadakis IA, Patrikidou A, Tsapakidis K, Stathakis NE, Papandreou CN. Combined treatment of colorectal cancer cell lines with aspirin and bortezomib. J Clin Onc 2007;25: abstract 14562.
77. Berenson JR, Ma HM, Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 2001;28:626-633. (Pubitemid 33138161)
78. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003;29(Suppl 1):33-39. (Pubitemid 36626290)
79. Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005;4:686-692. (Pubitemid 40601851)
80. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 2001;61:5926-5932. (Pubitemid 32769113)
81. Yunmbam MK, Li QQ, Mimnaugh EG, Kayastha GL, Yu JJ, Jones LN, et al. Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells. Int J Oncol 2001;19:741-748.
82. Adachi M, Zhang Y, Zhao X, Minami T, Kawamura R, Hinoda Y, et al. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin Cancer Res 2004;10:3853-3862. (Pubitemid 38697621)
83. Hougardy BM, Maduro JH, Van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EG, et al. Proteasome inhibitor MG132 sensitizes HPVpositive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer 2006;118:1892-1900.
84. Pajonk F, Pajonk K, McBride WH. Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 2000;47:1025-1032. (Pubitemid 30345603)
85. Pajonk F, Van Ophoven A, Weissenberger C, McBride WH. The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer 2005;5:76.
86. Goktas S, Baran Y, Ural AU, Yazici S, Aydur E, Basal S, et al. Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells. Urology 2010;75:793-798.
87. Grimes KR, Daosukho C, Zhao Y, Meigooni A, St ClairW. Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection. Int J Oncol 2005;27:1047-1052.
88. Kamer S, Ren Q, Dicker AP. Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341). Arch Gynecol Obstet 2009;279:41-46.
89. Weber CN, Cerniglia GJ, Maity A, Gupta AK. Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biol Ther 2007;6:156-159. (Pubitemid 46641617)
90. Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D, et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res 2008;14:5116-5123.
91. Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;63:1400-1412. (Pubitemid 41628035)
92. Vlashi E, Mattes M, Lagadec C, Donna LD, Phillips TM, Nikolay P, et al. Differential effects of the proteasome inhibitor NPI-0052 against glioma cells. Transl Oncol 2010;3:50-55.
93. Kubicek GJ, Werner-Wasik M, Machtay M, Mallon G, Myers T, Ramirez M, et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2009;74:433-439.
94. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998;58:4342-4348. (Pubitemid 28450035)
95. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998;5:1062-1075. (Pubitemid 29008220)
96. Dietrich C, Bartsch T, Schanz F, Oesch F, Wieser RJ. p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc Natl Acad Sci U S A 1996;93:10815-10819.
97. Hochwald SN, Lind DS, Malaty J, Copeland EM III, Moldawer LL, MacKay SL. Antineoplastic therapy in colorectal cancer through proteasome inhibition. Am Surg 2003;69:15-23.
98. Coquelle A, Mouhamad S, Pequignot MO, Braun T, Carvalho G, Vivet S, et al. Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells. Cell Death Differ 2006;13:873-875.
99. Kim OH, Lim JH, Woo KJ, Kim YH, Jin IN, Han ST, et al. Influence of p53 and p21Waf1 expression on G2/M phase arrest of colorectal carcinoma HCT116 cells to proteasome inhibitors. Int J Oncol 2004;24:935-941.
100. Ding WX, Ni HM, Chen X, Yu J, Zhang L, Yin XM. A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. Mol Cancer Ther 2007;6:1062-1069. (Pubitemid 46554577)
101. Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, et al. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res 2008;68:3379-3388.
102. Wu WK, Wu YC, Yu L, Li ZJ, Sung JJ, Cho CH. Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells. Biochem Biophys Res Commun 2008;374:258-263.
103. Wu WK, Volta V, Cho CH, Wu YC, Li HT, Yu L, et al. Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells. Biochem Biophys Res Commun 2009;386:598-601.
104. Chen S, Blank JL, Peters T, Liu XJ, Rappoli DM, Pickard MD, et al. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res 2010;70:4318-4326.
105. Loeffler-Ragg J, Mueller D, Gamerith G, Auer T, Skvortsov S, Sarg B, et al. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Mol Cancer Ther 2009;8:1995-2006.
106. Noonan EJ, Fournier G, Hightower LE. Surface expression of Hsp70B' in response to proteasome inhibition in human colon cells. Cell Stress Chaperones 2008;13:105-110.
107. Wu WK, Sung JJ, Wu YC, Li ZJ, Yu L, Cho CH. Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br J Pharmacol 2008;154:632-638. (Pubitemid 351744945)
108. Tankel K, Hay J, Ma R, Toy E, Larsson S, MacFarlane J, et al. Short-course preoperative radiation therapy for operable rectal cancer. Am J Surg 2002;183:509-511. (Pubitemid 34603418)
109. Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ, et al. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 2005;4:781-786. (Pubitemid 41351180)
110. Pitts TM, Morrow M, Kaufman SA, Tentler JJ, Eckhardt SG. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 2009;8:342-349.
111. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23:2840-2855. (Pubitemid 46179475)
112. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21. (Pubitemid 33741877)
113. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I (kappa) B kinase-beta. Nature 1998;396:77-80. (Pubitemid 28520452)
114. Babbar N, Ignatenko NA, Casero RA Jr, Gerner EW. Cyclooxygenaseindependent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem 2003;278:47762-47775. (Pubitemid 37523223)
115. Dihlmann S, Klein S, Doeberitz Mv MK. Reduction of beta-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2003;2:509-516.
116. Ignatenko NA, Babbar N, Mehta D, Casero RA Jr, Gerner EW. Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Mol Carcinog 2004;39:91-102. (Pubitemid 38167113)
117. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-3410.
118. Dikshit P, Chatterjee M, Goswami A, Mishra A, Jana NR. Aspirin induces apoptosis through the inhibition of proteasome function. J Biol Chem 2006;281:29228-29235. (Pubitemid 44507066)
119. Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 2005;11:5526-5533. (Pubitemid 41060829)
120. Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, et al. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 2006;107:2688-2697. (Pubitemid 44845625)
121. Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, et al. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. J Clin Oncol 2008;26:2320-2326.
122. Caponigro F, Lacombe D, Twelves C, Bauer J, Govaerts AS, Marreaud S, et al. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Eur J Cancer 2009;45:48-55.
123. O'Neil BH, Raftery L, Calvo BF, Chakravarthy AB, Ivanova A, Myers MO, et al. A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clin Colorectal Cancer 2010;9:119-125.
124. Iqbal S, Cole S, Yang D, Lara PN, Gumerlock PH, Shibata S, et al. Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: a California Cancer Consortium study. J Clin Onc 2004, ASCO Annu Meeting Proc (Post-Meeting Edition) 2004;22:2057.
125. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
126. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, MichalskiW, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:1215-1223. (Pubitemid 44547018)
127. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-646.
128. Marijnen CA, Nagtegaal ID, Klein Kranenbarg E, Hermans J, van de Velde CJ, Leer JW, et al. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001;19:1976-1984. (Pubitemid 32702542)
129. Pugh TJ, Chen C, Rabinovitch R, Eckhardt SG, Rusthoven KE, Swing R, et al. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int J Radiat Oncol Biol Phys 2010;78:521-526.